Τόμος 27 (2009) – Τεύχος 1 – Άρθρο 28 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση – Volume 27 (2009) – Issue 1– Article 28 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

Νικόλαος Ρεφενές^1,2, Juliane Bolbrinker², Γεώργιος Τάγαρης³, Antonio Orlacchio^4,5, Νικόλαος Δρακούλης¹, Reinhold Kreutz²

¹Φαρμακευτική Σχολή, Τμήμα Φαρμακευτικής Τεχνολογίας, Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών, Αθήνα, Ελλάδα; ²Institute of Clinical Pharmacology and Toxicology, Charité – Universitätsmedizin Berlin, Berlin, Germany; ³Νευρολογικό Τμήμα, Γ. Γεννηματάς Γενικό Νοσοκομείο, Αθήνα , Ελλάδα, ⁴Laboratory of Neurogenetics, CERC-IRCCS Santa Lucia, Rome, Italy, ⁵Department of Neuroscience, Università di Roma Tor Vergata, Rome, Italy

Nikolaos Refenes^1,2, Juliane Bolbrinker², George Tagaris³, Antonio Orlacchio^4,5, Nikolaos Drakoulis¹, Reinhold Kreutz²

¹Dep. of Pharmaceutical Technology, Faculty of Pharmacy, National & Kapodistrian University of Athens, Athens, Hellas; ²Institute of Clinical Pharmacology and Toxicology, Charité – Universitätsmedizin Berlin, Berlin, Germany; ³Neurologic Department, G. Genimatas General Hospital, Athens, Hellas; ⁴Laboratory of Neurogenetics, CERC-IRCCS Santa Lucia, Rome, Italy, ⁵Department of Neuroscience, Università di Roma Tor Vergata, Rome, Italy

2. Forno LS: Neuropathology of Parkinson’s disease. J. Neuropathol. Exp. Neurol. 55: 259-272 (1996)

3. Volles M.J., Lansbury P.T.,Jr: Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson’s disease. Biochemistry 42: 7871-7878 (2003)

4. Jensen P.H., Hager H., Nielsen M.S., et al.: alpha-synuclein binds to Tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356. J. Biol. Chem. 274: 25481-25489 (1999)

5. Giasson B.I., Forman M.S., Higuchi M., et al.: Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300: 636-640 (2003)

6. Higuchi M., Lee V.M., Trojanowski J.Q.: Tau and axonopathy in neurodegenerative disorders. Neuromol. Med. 2: 131-150 (2002)

7. Baker M., Litvan I., Houlden H., et al.: Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum. Mol. Genet. 8: 711-715 (1999)

8. Fidani L., Kalinderi K., Bostantjopoulou S., et al.: Association of the Tau haplotype with Parkinson’s disease in the Greek population. Mov. Disord. 21: 1036-1039 (2006)

9. Fung H.C., Xiromerisiou G., Gibbs J.R., et al.: Association of tau haplotype-tagging polymorphisms with Parkinson’s disease in diverse ethnic Parkinson’s disease cohorts. Neurodegener. Dis. 3: 327-333 (2006)

10. Stephens M., Smith N.J., Donnelly P.: A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 68: 978-989 (2001)

11. Skipper L., Wilkes K., Toft M., et al.: Linkage disequilibrium and association of MAPT H1 in Parkinson disease. Am. J. Hum. Genet. 75: 669-677 (2004)

12. Zabetian C.P., Hutter C.M., Factor S.A., et al.: Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson’s disease. Ann. Neurol. 62: 137-144 (2007)

13. Tobin J.E., Latourelle J.C., Lew M.F., et a.l: Haplotypes and gene expression implicate the MAPT region for Parkinson disease. The GenePD Study. Neurology 71: 28-34 (2008)